Tesamorelin Research Guide: GHRH Analog, Visceral Fat & Clinical Studies

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the full 44-amino acid GHRH(1-44) sequence conjugated to a trans-3-hexenoic acid moiety at the N-terminus. This structural modification significantly extends plasma half-life relative to native GHRH while preserving full GHRH receptor agonist activity. Tesamorelin is one of the most clinically characterized GHRH analogs available, it is FDA-approved under the brand name Egrifta® for the treatment of HIV-associated lipodystrophy (excess visceral adipose tissue accumulation in HIV-positive patients on antiretroviral therapy) and has been studied in aging-related body composition research, nonalcoholic fatty liver disease (NAFLD), and cognitive function.

For research use only. Not intended for human or veterinary use.

Background: GHRH and the GH Secretory Axis

Growth hormone-releasing hormone (GHRH) is a 44-amino acid hypothalamic peptide that binds GHRH receptors (GHRHr) on pituitary somatotroph cells, stimulating GH synthesis and pulsatile secretion. GHRH acts synergistically with the ghrelin receptor (GHS-R1a) system: GHRH activates Gs-coupled adenylate cyclase (cAMP/PKA pathway) while GHS-R1a agonists (GHRPs) activate Gq-coupled calcium signaling, together producing GH pulses 3–10 times greater than either alone. Somatostatin, released from hypothalamic periventricular neurons, inhibits GH release and GH-stimulated IGF-1 production.

Native GHRH has a plasma half-life of only ~7 minutes due to rapid cleavage by dipeptidyl peptidase IV (DPP-IV) at the Ala2 position. Tesamorelin’s trans-3-hexenoic acid modification at the N-terminus sterically hinders DPP-IV cleavage, extending the effective half-life to approximately 26–38 minutes, sufficient for meaningful pituitary stimulation and IGF-1 elevation with once-daily administration.

Structure and Key Properties

• Structure: Trans-3-hexenoic acid conjugated GHRH(1-44)NH2
• Molecular weight: ~5,135 Da (larger than peptide GHRPs due to full GHRH sequence)
• Receptor: GHRH receptor (GHRHr), Gs-coupled; high affinity, full agonist
• Half-life: ~26–38 minutes (significantly longer than native GHRH’s ~7 min)
• IGF-1 elevation: Once-daily SC administration produces sustained IGF-1 elevation, with effects maintained over months of treatment in clinical studies
• FDA status: Approved for HIV-associated lipodystrophy (Egrifta®, Egrifta SV®), provides extensive human pharmacokinetic and safety data

Mechanism of Action

GHRHr Activation and GH Pulsatility Restoration

Tesamorelin binds GHRHr on pituitary somatotrophs with high affinity, activating Gs protein-coupled adenylate cyclase and elevating intracellular cAMP. PKA activation downstream phosphorylates transcription factors driving GH gene expression and triggers calcium-dependent GH vesicle exocytosis. Unlike GHRP secretagogues (which continuously stimulate GH release), tesamorelin acts through the hypothalamic-pituitary feedback loop, stimulating endogenous GH pulses that maintain the normal pulsatile pattern and preserve physiological IGF-1 feedback regulation. This physiological preservation is mechanistically important: tesamorelin elevates IGF-1 but maintains somatostatin feedback, producing GH profiles more similar to endogenous secretion than exogenous GH administration.

Visceral Fat Mobilization

GH’s lipolytic effects are regionally concentrated in visceral adipose tissue (VAT), intra-abdominal fat surrounding the organs. VAT expresses higher densities of GH receptors than subcutaneous fat and is more responsive to GH-stimulated lipolysis. GH-deficient states (including aging-associated GH decline) preferentially expand VAT, contributing to metabolic syndrome risk. Tesamorelin-stimulated GH elevation produces preferential visceral lipolysis: mobilization of VAT triglycerides into free fatty acids for oxidation. This mechanistic selectivity, targeting metabolically hazardous visceral fat, distinguishes tesamorelin’s body composition effects from general weight loss interventions.

Key Research Findings

HIV-Associated Lipodystrophy (FDA-Approved Indication)

The pivotal trials supporting tesamorelin’s FDA approval (LIPO-AA and LIPO-AB) enrolled HIV-positive patients with excess visceral fat accumulation on antiretroviral therapy, a lipodystrophy syndrome characterized by VAT excess, dyslipidemia, and increased cardiometabolic risk. Falutz et al. (2007, 2010) reported that 26 weeks of daily tesamorelin (2 mg SC) reduced VAT area by approximately 18% versus placebo by CT scan quantification, with significant improvements in triglycerides and trunk fat ratio. The effect was maintained at 52 weeks and reversed within 6 months of discontinuation, confirming the GH-dependent mechanism rather than permanent structural change.

Aging-Related Body Composition

Age-related GH decline (somatopause) is associated with VAT accumulation, reduced lean mass, and impaired metabolic function. Veldhuis et al. and Sigalos & Pastuszak examined tesamorelin in aging populations, documenting significant reductions in VAT and trunk fat with maintained or improved lean mass over treatment periods. Unlike exogenous GH (which produces water retention, insulin resistance, and arthralgias at replacement doses), tesamorelin’s physiological GH stimulation profile produced a more favorable tolerability profile in aging research subjects, consistent with preserved somatostatin feedback limiting supraphysiological GH excursions.

Nonalcoholic Fatty Liver Disease (NAFLD)

Visceral fat accumulation drives hepatic fat deposition via portal free fatty acid flux, and GH deficiency is an established risk factor for NAFLD. Stanley et al. (2014) conducted a randomized trial of tesamorelin in HIV-positive patients with NAFLD, reporting significant reductions in liver fat fraction (measured by MR spectroscopy) compared to placebo over 6 months. The magnitude of liver fat reduction correlated with VAT reduction, consistent with the portal hypothesis. This NAFLD indication has generated interest in tesamorelin as a research tool for liver fat biology in metabolic disease models.

Cognitive Function Research

IGF-1 plays important roles in neuronal survival, synaptic plasticity, and hippocampal neurogenesis. Baker et al. (2012) examined tesamorelin’s effects on cognitive function in healthy older adults, reporting improved executive function scores in tesamorelin-treated subjects versus placebo, with effects correlating with IGF-1 elevation. More recent work has examined tesamorelin in mild cognitive impairment (MCI) models, exploring whether IGF-1 restoration can slow cognitive decline, a hypothesis supported by the established role of IGF-1 in brain aging biology.

Reconstitution Protocol

Tesamorelin is supplied as a lyophilized powder requiring reconstitution with bacteriostatic water prior to research use.

• Inject bacteriostatic water slowly along the inner wall of the vial; do not direct the stream onto the lyophilized powder
• Gently swirl until fully dissolved; solution should be clear and colorless; do not shake
• Common research concentration: 1–2 mg/mL
• Refrigerate reconstituted solution at 2–8°C; stable approximately 3–4 weeks; protect from light
• Do not freeze reconstituted solution; lyophilized powder may be stored at -20°C

References

• Falutz, J., Allas, S., Blot, K., Potvin, D., Kotler, D., Somero, M., … & Grinspoon, S. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359–2370.
• Falutz, J., Mamputu, J. C., Potvin, D., Moyle, G., Soulban, G., Loughrey, H., … & Grinspoon, S. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat. Journal of Acquired Immune Deficiency Syndromes, 53(3), 311–322.
• Stanley, T. L., Feldpausch, M. N., Oh, J., Branch, K. L., Lee, H., Torriani, M., & Grinspoon, S. K. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. Journal of the American Medical Association, 312(4), 380–389.
• Baker, L. D., Barsness, S. M., Borson, S., Merriam, G. R., Friedman, S. D., Craft, S., & Vitiello, M. V. (2012). Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment. Archives of Neurology, 69(11), 1420–1429.

All content on this site is intended strictly for in vitro research and laboratory use. Products sold by Exceed Enhancement are not approved by the FDA and are not intended for human consumption, therapeutic use, or veterinary application.

Research-Grade Tesamorelin Available

Exceed Enhancement offers research-grade Tesamorelin for qualified research applications. View product specifications and ordering information →